Patient Rating:

No Rating Available?

Stephen L. Lessnick, M.D., Ph.D.

Patient Rating:

No Rating Available?

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 662-4700 Primary Children's Hospital
Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City, UT 84113

Bio

Stephen Lessnick, MD, PhD, is a Huntsman Cancer Institute (HCI) investigator and member of the Nuclear Control of Cell Growth and Differentiation program. He is a Professor in the Division of Pediatric Hematology/Oncology, Department of Pediatrics at the University of Utah School of Medicine, as well as an Adjunct Professor in the Department of Oncological Sciences, and an Adjunct Professor in the Department of Bioengineering. He is the Director of the Center for Children's Cancer Research. He holds a Jon and Karen Huntsman Presidential Professorship in Cancer Research.

The Lessnick Lab studies Ewing's sarcoma as a model for pediatric tumor development. Ewing's sarcoma is a prototypical tumor that has a peak incidence in the teenage years. A chromosomal translocation (an abnormality that occurs when chromosomes break and the fragments rejoin to other chromosomes) characterizes Ewing's sarcoma. Learning details of how the cancer-causing protein created by this translocation functions could help resolve questions about the differences between pediatric and adult tumors, and between sarcomas and other forms of cancer. Additionally, the Lessnick Lab is interested in developing new therapeutic interventions for children with cancer.

Dr. Lessnick earned his bachelor's degree from Brandeis University followed by MD and PhD degrees from the University of California, Los Angeles (UCLA) as part of the Medical Scientist Training Program (MSTP). He conducted his internship and residency at Children's Hospital in Boston, Massachusetts, followed by a fellowship in pediatric hematology/oncology at the Dana-Farber Cancer Institute and Children's Hospital. His fellowship/postdoctoral research was performed in the Pediatric Oncology Department at the Dana-Farber Cancer Institute.

Board Certification and Academic Information

Academic Departments Pediatrics - Professor
Oncological Sciences - Adjunct Professor
Orthopaedics - Adjunct Professor
Academic Divisions Pediatric Hematology/Oncology
Cancer Center Programs Nuclear Control of Cell Growth & Differentiation

Academic Profile

Research Interests

  • Pediatric Cancer Biology
  • Ewing's Sarcoma
  • Pediatric Cancer Development

Board Certification and Academic Information

Academic Departments Pediatrics - Professor
Oncological Sciences - Adjunct Professor
Orthopaedics - Adjunct Professor
Academic Divisions Pediatric Hematology/Oncology
Cancer Center Programs Nuclear Control of Cell Growth & Differentiation

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 585-9268 Huntsman Cancer Institute
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Stephen Lessnick, MD, PhD, is a Huntsman Cancer Institute (HCI) investigator and member of the Nuclear Control of Cell Growth and Differentiation program. He is a Professor in the Division of Pediatric Hematology/Oncology, Department of Pediatrics at the University of Utah School of Medicine, as well as an Adjunct Professor in the Department of Oncological Sciences, and an Adjunct Professor in the Department of Bioengineering. He is the Director of the Center for Children's Cancer Research. He holds a Jon and Karen Huntsman Presidential Professorship in Cancer Research.

The Lessnick Lab studies Ewing's sarcoma as a model for pediatric tumor development. Ewing's sarcoma is a prototypical tumor that has a peak incidence in the teenage years. A chromosomal translocation (an abnormality that occurs when chromosomes break and the fragments rejoin to other chromosomes) characterizes Ewing's sarcoma. Learning details of how the cancer-causing protein created by this translocation functions could help resolve questions about the differences between pediatric and adult tumors, and between sarcomas and other forms of cancer. Additionally, the Lessnick Lab is interested in developing new therapeutic interventions for children with cancer.

Dr. Lessnick earned his bachelor's degree from Brandeis University followed by MD and PhD degrees from the University of California, Los Angeles (UCLA) as part of the Medical Scientist Training Program (MSTP). He conducted his internship and residency at Children's Hospital in Boston, Massachusetts, followed by a fellowship in pediatric hematology/oncology at the Dana-Farber Cancer Institute and Children's Hospital. His fellowship/postdoctoral research was performed in the Pediatric Oncology Department at the Dana-Farber Cancer Institute.

Education

Education History

Type School Degree
Postdoctoral Fellowship Dana-Farber Cancer Institute - Todd Golub, MD
Hematology/Oncology
Postdoctoral Fellow
Fellowship Dana-Farber Cancer Institute, Harvard - Boston
Hematology/Oncology
Fellow
Residency Children's Hospital, Harvard - Boston
Pediatrics
Resident
Internship Children's Hospital, Harvard - Boston
Pediatrics
Intern
Professional Medical University of California
Medicine
M.D.
Doctoral Training University of California - Christopher Denny Lab
Molecular Biology
Ph.D.
Undergraduate Brandeis University
Biochemistry
B.A.

Publications

Selected Provider Publications

Journal Article

  1. Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL (2013). Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene, 32(42), 5089-100.
  2. Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL (2013). A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group. Front Oncol, 3, 57.
  3. Wiles ET, Lui-Sargent B, Bell R, Lessnick SL (2013). BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma. PLoS One, 8(3), e59369.
  4. Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER (2013). Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Front Oncol, 3, 141.
  5. Sankar S, Tanner JM, Bell R, Chaturvedi A, Randall RL, Beckerle MC, Lessnick SL (2013). A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma. Mol Cell Biol, 33(22), 4448-60.
  6. Sankar S, Gomez NC, Bell R, Patel M, Davis IJ, Lessnick SL, Luo W (2013). EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma. Genes Cancer, 4(5-6), 213-23.
  7. Wiles ET, Bell R, Thomas D, Beckerle M, Lessnick SL (2013). ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma. Genes Cancer, 4(11-12), 486-500.
  8. DuBois SG, Goldsby R, Segal M, Woo J, Copren K, Kane JP, Pullinger CR, Matthay KK, Witte J, Lessnick SL, Robison LL, Bhatia S, Strong LC (2012). Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer, 59(1), 52-6.
  9. Luo W, Milash B, Dalley B, Smith R, Zhou H, Dutrow N, Cairns BR, Lessnick SL (2012). Antibody detection of translocations in Ewing sarcoma. EMBO Mol Med, 4(6), 453-61.
  10. Calvert GT, Randall RL, Jones KB, Cannon-Albright L, Lessnick S, Schiffman JD (2012). At-risk populations for osteosarcoma: the syndromes and beyond. Sarcoma, 2012, 152382.
  11. Spraker HL, Price SL, Chaturvedi A, Schiffman JD, Jones KB, Lessnick SL, Beckerle M, Randall RL (2012). The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm. Front Oncol, 2, 2.
  12. Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schafer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R (2012). The first European interdisciplinary ewing sarcoma research summit. Front Oncol, 2, 54.
  13. Beck R, Monument MJ, Watkins WS, Smith R, Boucher KM, Schiffman JD, Jorde LB, Randall RL, Lessnick SL (2012). EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations. Cancer Genet, 205(6), 304-12.
  14. Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, Kinsey M, Zhou H, Boucher KM, Randall RL, Jones KB, Lucas D, Rosenberg A, Thomas D, Lessnick SL, Schiffman JD (2012). Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genet, 205(7-8), 391-404.
  15. Evans CH, Liu F, Porter RM, OSullivan RP, Merghoub T, Lunsford EP, Robichaud K, Van Valen F, Lessnick SL, Gebhardt MC, Wells JW (2012). EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors. Clin Cancer Res, 18(19), 5341-51.
  16. Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC (2012). The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. Genes Cancer, 3(2), 102-16.
  17. Monument MJ, Lessnick SL, Schiffman JD, Randall RT (2012). Microsatellite instability in sarcoma: fact or fiction? ISRN Oncol, 2012, 473146.
  18. Jones KB, Schiffman JD, Kohlmann W, Randall RL, Lessnick SL, Cannon-Albright LA (2011). COMPLEX GENOTYPE SARCOMAS DISPLAY FAMILIAL INHERITANCE INDEPENDENT OF KNOWN CANCER PREDISPOSITION SYNDROMES. Cancer Epidemiol Biomarkers Prev.
  19. Lessnick SL, Kovar H, Houghton P (2011). The molecular basis of sarcoma. Sarcoma, 2011, 864130.
  20. Sankar S, Lessnick SL (2011). Promiscuous partnerships in Ewing's sarcoma. Cancer Genet, 204(7), 351-65.
  21. Joyner DE, Jones KB, Lessnick SL, Schiffman JD, Randall RL (2011). Potential for modulation of the fas apoptotic pathway by epidermal growth factor in sarcomas. Sarcoma, 2011, 847409.
  22. Luo W, Kinsey M, Schiffman JD, Lessnick SL (2011). Glutathione s-transferases in pediatric cancer. Front Oncol, 1, 39.
  23. Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, Garofalo C, Meschini S, Astolfi A, Colombo MP, Lessnick SL, Picci P, Scotlandi K (2010). CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest, 120(3), 668-80.
  24. Randall RL, Lessnick SL, Jones KB, Gouw LG, Cummings JE, Cannon-Albright L, Schiffman JD (2010). Is There a Predisposition Gene for Ewing's Sarcoma? J Oncol, 2010, 397632.
  25. van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor ER (2010). Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol, 28(12), 1989-94.
  26. Gangwal K, Close D, Enriquez CA, Hill CP, Lessnick SL (2010). Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma. Genes Cancer, 1(2), 177-187.
  27. DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Grier HE, Stegmaier K (2009). Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer, 52(3), 324-7.
  28. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL (2009). GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene.
  29. Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL (2009). EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res, 69(23), 9047-55.

Review

  1. Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N (2013). Children's Oncology Group's 2013 blueprint for research: bone tumors. [Review]. Pediatr Blood Cancer, 60(6), 1009-15.
  2. Lessnick SL, Ladanyi M (2012). Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. [Review]. Annu Rev Pathol, 7, 145-59.
  3. Kowalewski AA, Randall RL, Lessnick SL (2011). Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis. [Review]. Sarcoma, 2011, 598704.
  4. Toomey EC, Schiffman JD, Lessnick SL (2010). Recent advances in the molecular pathogenesis of Ewing's sarcoma. [Review]. Oncogene, 29(32), 4504-16.
  5. Braun BS, Lessnick SL (2009). Pediatric malignancies: update on sarcomas and leukemia development in children. [Review]. Current Opinion in Genetics & Development, 19(1), 92-6.
  6. Lessnick SL, Dei Tos AP, Sorensen PH, Dileo P, Baker LH, Ferrari S, Hall KS (2009). Small round cell sarcomas. [Review]. Semin Oncol, 36(4), 338-46.

Clinical Trials

Video & News

Video